Russian pharmacies began to experience a shortage of drugs for recurrent heart attacks – the drug Effient (prasugrel) from the American pharmaceutical company Eli Lilly. The newspaper reported this “Vedomosti” With reference to the Ministry of Health of the Russian Federation.
The ministry reported that the remaining stock of the drug will last less than a month.
According to the CEO of the pharmacy market Zdravcity, the official distributor of the Servier company Effient in Russia, Dmitry Popov, informed partners that the supply of the drug was discontinued in September 2023 and there are no plans to resume sales.
The newspaper states that there is currently a shortage of Effient in pharmacies in most regions of Russia. According to data on the Uteka portal, now Moscow, Moscow region, St. Not available at retail outlets in St. Petersburg and other regions.
The Ministry of Health of the Russian Federation emphasized that medicines from other manufacturers arrive in Russia without defects and, if necessary, can be prescribed by the relevant doctor. Effient has analogues in the form of drugs with active ingredients clopidogrel, ticagrelor and others, there is no shortage of such drugs on the Russian market.
In December, TASS reported, based on research data from the Contemporary Media Institute reportedIt is stated that in 2023, one third of Russians will face medicine shortages and almost all (91%) will face an increase in prices.
Those who have previously participated in the pharmaceutical market said About the state of pharmaceutical production in Russia.